Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 20888625)

1.

The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.

Kothari R, Nagel C, Koopmeiners JS, Ivy JJ, Geller M, Salani R, Argenta PA.

Gynecol Oncol. 2010 Dec;119(3):491-5. doi: 10.1016/j.ygyno.2010.08.026.

PMID:
20888625
2.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.

PMID:
22446622
3.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA.

J Clin Oncol. 2011 Dec 10;29(35):4662-8. doi: 10.1200/JCO.2011.36.1352. Epub 2011 Nov 7.

4.

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.

Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.

Gynecol Oncol. 2010 Mar;116(3):340-4. doi: 10.1016/j.ygyno.2009.10.054. Epub 2009 Nov 17.

PMID:
19922987
5.

Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.

Seamon LG, Carlson MJ, Richardson DL, Cohn DE, Fowler JM, Copeland LJ, O'Malley DM.

Int J Gynecol Cancer. 2009 Oct;19(7):1195-8. doi: 10.1111/IGC.0b013e3181b33d5b.

PMID:
19823054
6.

Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.

Lesnock JL, Richard SD, Zorn KK, Krivak TC, Beriwal S, Sukumvanich P, McBee WC Jr, Kelley JL, Edwards RP.

Gynecol Oncol. 2010 Mar;116(3):345-50. doi: 10.1016/j.ygyno.2009.11.009. Epub 2009 Dec 2.

PMID:
19959211
7.

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS.

J Clin Oncol. 2003 Apr 1;21(7):1313-9.

PMID:
12663720
8.

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.

Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS.

Gynecol Oncol. 2009 Mar;112(3):444-9. doi: 10.1016/j.ygyno.2008.10.028. Epub 2009 Jan 12.

9.

Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.

Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP.

Int J Gynecol Cancer. 2012 Feb;22(2):232-7. doi: 10.1097/IGC.0b013e318234f833.

PMID:
22080886
10.

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.

Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S.

Gynecol Oncol. 2012 Oct;127(1):51-4. doi: 10.1016/j.ygyno.2012.05.026. Epub 2012 May 30.

PMID:
22659193
11.

Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.

Oaknin A, Roda D, González-Martín A, Chiva L, García-Donas J, de Juan A, Redondo A, Martínez S, García Y, Catot S, Ponce J, Del Campo JM, Cervantes A, Poveda A.

Int J Gynecol Cancer. 2011 Aug;21(6):1048-55. doi: 10.1097/IGC.0b013e31821ee777.

PMID:
21738038
12.

Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.

Landrum LM, Hyde J Jr, Mannel RS, McMeekin DS, Moore KN, Walker JL.

Gynecol Oncol. 2011 Sep;122(3):527-31. doi: 10.1016/j.ygyno.2011.05.022. Epub 2011 Jun 12.

PMID:
21664657
13.

Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.

Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.

Gynecol Oncol. 2000 Oct;79(1):28-32.

PMID:
11006026
14.

An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.

Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J.

Gynecol Oncol. 2009 Apr;113(1):63-7. doi: 10.1016/j.ygyno.2008.12.035. Epub 2009 Feb 7.

PMID:
19201457
15.
16.

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD.

Gynecol Oncol. 2007 Sep;106(3):476-81. Epub 2007 Aug 3.

PMID:
17688927
17.
18.

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group.

N Engl J Med. 2006 Jan 5;354(1):34-43.

19.

Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.

Chin SN, Pinto V, Rosen B, Oza A, Dodge J, Murphy J, Mackay H.

Gynecol Oncol. 2009 Mar;112(3):450-4. doi: 10.1016/j.ygyno.2008.11.021. Epub 2009 Jan 10.

PMID:
19135709
20.

Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.

Nagao S, Fujiwara K, Ohishi R, Nakanishi Y, Iwasa N, Shimizu M, Goto T, Shimoya K.

Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1210-4. doi: 10.1111/j.1525-1438.2008.01192.x. Epub 2008 Feb 15.

PMID:
18284454
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk